These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29758480)

  • 21. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
    Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
    O'Connor SM; Beriwal S; Dabbs DJ; Bhargava R
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):268-72. PubMed ID: 20186046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy.
    Khoury T; Zakharia Y; Tan W; Kulkarni S; Liu W; Zhang S; Wilding GE; Edge S
    Breast J; 2011; 17(2):180-6. PubMed ID: 21306471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
    BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR.
    Caselli E; Pelliccia C; Teti V; Bellezza G; Mandarano M; Ferri I; Hartmann K; Laible M; Sahin U; Varga Z; Lupi C; Stracci F; Sidoni A
    PLoS One; 2021; 16(9):e0255580. PubMed ID: 34555047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.
    Aimi F; Procopio MG; Alvarez Flores MT; Brouland JP; Piazzon N; Brajkovic S; Dupouy DG; Gijs M; de Leval L
    Virchows Arch; 2019 Sep; 475(3):313-323. PubMed ID: 31267199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
    Oluwasola AO; Malaka D; Khramtsov AI; Ikpatt OF; Odetunde A; Adeyanju OO; Sveen WE; Falusi AG; Huo D; Olopade OI
    Ann Diagn Pathol; 2013 Dec; 17(6):526-30. PubMed ID: 24095629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation and Characterization of Novel Diagnostic Mouse Monoclonal Antibodies Against Human Estrogen Receptor Alpha and Progesterone Receptor.
    Hassanzadeh Makoui M; Mobini M; Khoshnoodi J; Judaki MA; Bahadori T; Ahmadi Zare H; Golsaz-Shirazi F; Moradi Tabriz H; Madjd Z; Jeddi-Tehrani M; Zarnani AH; Amiri MM; Shokri F
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2999-3007. PubMed ID: 36172662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concordance of immunohistochemistry between core needle biopsy and surgical resection of breast cancer.
    Kombak FE; Şahin H; Mollamemişoğlu H; Önem İ; Kaya H; Buğdaycı O; Arıbal E
    Turk J Med Sci; 2017 Dec; 47(6):1791-1796. PubMed ID: 29306240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.